The 36-month beta value for EDIT is also noteworthy at 1.90. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 0 rating it as “overweight,” 9 rating it as “hold,” and 0 rating it as “sell.”
The public float for EDIT is 81.77M, and at present, short sellers hold a 21.08% of that float. The average trading volume of EDIT on November 25, 2024 was 2.05M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EDIT) stock’s latest price update
Editas Medicine Inc (NASDAQ: EDIT)’s stock price has plunge by 2.00relation to previous closing price of 2.44. Nevertheless, the company has seen a -1.24% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-19 that Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera – Chief Financial Officer Conference Call Participants Dae Gon Ha – Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour.
EDIT’s Market Performance
EDIT’s stock has fallen by -1.24% in the past week, with a monthly drop of -21.74% and a quarterly drop of -34.85%. The volatility ratio for the week is 6.46% while the volatility levels for the last 30 days are 7.35% for Editas Medicine Inc The simple moving average for the last 20 days is -12.64% for EDIT stock, with a simple moving average of -51.83% for the last 200 days.
EDIT Trading at -21.58% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.71% of loss for the given period.
Volatility was left at 7.35%, however, over the last 30 days, the volatility rate increased by 6.46%, as shares sank -23.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.12% lower at present.
During the last 5 trading sessions, EDIT fell by -1.39%, which changed the moving average for the period of 200-days by -66.64% in comparison to the 20-day moving average, which settled at $2.85. In addition, Editas Medicine Inc saw -75.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EDIT starting from Mei Baisong, who sale 518 shares at the price of $3.42 back on Sep 04 ’24. After this action, Mei Baisong now owns 133,895 shares of Editas Medicine Inc, valued at $1,774 using the latest closing price.
O’Neill Gilmore Neil, the CEO of Editas Medicine Inc, sale 1,555 shares at $3.42 during a trade that took place back on Sep 04 ’24, which means that O’Neill Gilmore Neil is holding 313,724 shares at $5,325 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -3.7 for the present operating margin
- 0.9 for the gross margin
The net margin for Editas Medicine Inc stands at -3.41. The total capital return value is set at -0.9. Equity return is now at value -78.56, with -50.61 for asset returns.
Based on Editas Medicine Inc (EDIT), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -11.09. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -65.88.
Currently, EBITDA for the company is -163.12 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 2.4. The receivables turnover for the company is 490.14for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
In summary, Editas Medicine Inc (EDIT) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
